Free Trial

AMAG Pharmaceuticals (AMAG) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
Average Volume
950,664 shs
Market Capitalization
$477.47 million
P/E Ratio
Dividend Yield
Price Target
AMAG stock logo

About AMAG Pharmaceuticals Stock (NASDAQ:AMAG)

AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

AMAG Stock News Headlines

AMAG Technology Introduces Symmetry Control Room
AMAG Technology Announces Company Badge in Google Wallet
Vera Therapeutics Appoints Robert Brenner As CMO
AMAG's Feraheme Closer to Approval
AMAG Austria Metall AG
Landsdowne Labs Names Bryan Laulicht CEO
CA 125 Test Market Research | 2023-2030
Nanometals Market Research | 2023-2030
See More Headlines
Receive AMAG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AMAG Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings

Industry, Sector and Symbol

Pharmaceutical Preparations
Current Symbol
Year Founded


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$327.75 million
Book Value
$7.37 per share


Free Float
Market Cap
$477.47 million
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. William K. Heiden (Age 60)
    CEO, Pres & Director
    Comp: $1.28M
  • Mr. Anthony Casciano (Age 43)
    Exec. VP & COO
    Comp: $625.19k
  • Mr. Joseph D. Vittiglio (Age 48)
    Exec. VP, Gen. Counsel, Chief Bus. Officer & Corp. Sec.
    Comp: $672.28k
  • Mr. Scott D. Myers M.B.A. (Age 54)
    Pres, CEO & Director
  • Mr. Brian Piekos (Age 46)
    Exec. VP & CFO
  • Ms. Linda S. Lennox
    VP of Investor Relations & Corp. Communications
  • Mr. Amit Verma
    VP of Marketing
  • Ms. Kelly Schick
    Sr. VP, Chief HR Officer & Head of Corp. Engagement
  • Dr. Laura Williams M.D.
    M.P.H., Sr. VP of Clinical Devel.
  • Mr. Peter Bawin
    Sr. VP & GM of Cord Blood Registry

AMAG Stock Analysis - Frequently Asked Questions

How were AMAG Pharmaceuticals' earnings last quarter?

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) issued its quarterly earnings results on Monday, May, 11th. The specialty pharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.27. The specialty pharmaceutical company had revenue of $68.66 million for the quarter, compared to analyst estimates of $64.95 million. AMAG Pharmaceuticals had a negative trailing twelve-month return on equity of 16.92% and a negative net margin of 74.93%.
Read the conference call transcript

What other stocks do shareholders of AMAG Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AMAG Pharmaceuticals investors own include Palatin Technologies (PTN), Bausch Health Companies (BHC), Broadcom (AVGO), Gilead Sciences (GILD), Netflix (NFLX), Energy Transfer (ET), Ford Motor (F), Tesla (TSLA) and NVIDIA (NVDA).

This page (NASDAQ:AMAG) was last updated on 5/23/2024 by Staff

From Our Partners